21 results
8-K
EX-99.5
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
utilizes third parties to, among other things, manufacture raw materials and Kineta’s product candidates, components, parts and consumables … affect the availability or cost of goods and services, including raw materials and other natural resources, necessary to run Kineta’s business
424B3
KA
Kineta Inc
10 Nov 22
Prospectus supplement
4:21pm
.
Kineta currently utilizes third parties to, among other things, manufacture raw materials and Kineta’s product candidates, components, parts
425
6ud0w9tpm
6 Jun 22
Business combination disclosure
4:05pm
8-K
EX-2.1
u5j0 k02l3
6 Jun 22
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
4:02pm
8-K
EX-10.1
t9eix41ixacrcj3561
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
424B3
ihxlou0til9
12 Nov 20
Prospectus supplement
6:08am
S-4
hx85y dvlm
23 Sep 20
Registration of securities issued in business combination transactions
4:50pm
8-K
EX-2.1
qj05x53izll6j7x6
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
8-K
EX-2.2
50a5em1l5kik9k8whl
24 Aug 20
Yumanity Therapeutics and Proteostasis Therapeutics Announce
5:31pm
425
EX-2.2
8ijaa84 u2hk
24 Aug 20
Business combination disclosure
5:28pm